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Abstract
Background: The prognostic and predictive abilities of 18F-fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) coupled with conventional computed tomography (CT) have not been studied
in patients with unresectable colorectal liver metastases (uCRLM) treated with combined hepatic arte-
rial infusion (HAI) and systemic chemotherapy.
Objectives: The ability of PET-CT metabolic response parameters to predict conversion to resectabil-
ity and oncologic outcome in this setting was evaluated.
Methods: Thirty-eight patients undergoing serial PET-CT as part of a Phase II trial of HAI and sys-
temic chemotherapy for uCRLM were included. Metabolic response was determined as the percentage
change in standard uptake value (SUV) and total lesion glycolysis (TLG). Conversion to resection, over-
all survival (OS), progression-free survival (PFS) and recurrence-free survival were evaluated using
standard statistics.
Results: Volumetric response sufficient to facilitate resection was seen in 53% of patients after a
median of 5 months of therapy. Median follow-up was 38 months (range: 32–52 months). Median OS
was not reached [95% confidence interval (CI) 32 months–unknown] and 3-year OS was 54% (range:
33–71%). Median PFS was 13 months (95% CI 6–21 months) and 3 year PFS was 10% (range:
3–20%). Neither baseline values nor the percentage change in any of the metabolic parameters evalu-
ated correlated with conversion to resection, survival variables or hepatic recurrence on Cox regression
analysis.
Conclusions: Pre- and post-treatment PET-related metabolic parameters do not predict conversion
to resection or oncologic outcome in patients with uCRLM treated with HAI and systemic chemother-
apy. Metabolic parameters should not be used to monitor response or to determine prognosis in these
patients.
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Introduction
Approximately 20% of patients with colorectal cancer have
synchronous colorectal liver metastases (CRLM). Additionally,
20–30% will develop metachronous liver metastases.1 Hepatic
resection is the treatment of choice in the 10–20% of patients
in whom complete resection is feasible.1–4 In the remaining
patients, chemotherapy constitutes the main therapeutic
option. However, a subset of these patients experience signifi-
cant volumetric response that is sufficient to allow resection
with curative intent and thus prolonged survival.5–8 Various
combination regimens of intrahepatic arterial and systemic
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chemotherapy have been shown to achieve conversion to
resectability in 30–50% of recipients.7,9,10
Adequate staging is germane to identify patients in whom
complete resection is likely. Some advocate the routine use of
18F-fluorodeoxyglucose (18F-FDG) positron emission tomog-
raphy (PET) coupled with conventional computed tomography
(CT) in the work-up of patients with CRLM, particularly for
the evaluation of extrahepatic disease.11–15 A recent meta-
analysis suggested that 18F-FDG PET-CT has higher accuracy
than CT alone for the detection of both hepatic and extrahe-
patic CRLM and that its routine use may lead to a change in
therapy in 9–66% of patients.16 A recent trial, however, which
randomized patients with resectable CRLM to undergo preop-
erative PET-CT and evaluated changes in surgical management
subsequent to it, found it had no impact on surgical planning
compared with CT alone.17
The use of FDG PET-CT for restaging and evaluation of
response after chemotherapy in patients with initially unresec-
table CRLM is less clearly defined. Metabolic response to treat-
ment has been reported to represent a predictive and prognostic
biomarker in other malignancies.18–23 However, studies focusing
on primary24,25 and metastatic26 colorectal cancer have failed to
prove FDG PET-CT an effective biomarker, and its sensitivity to
detect metastasis after conversion chemotherapy has been ques-
tioned.27,28
Although the role of FDG PET-CT in staging, restaging and
patient selection and as a prognostic marker has been an area of
study and debate in patients with CRLM receiving systemic che-
motherapy, the metabolic response parameters after treatment
with hepatic arterial infusion pump (HAIP) in patients with un-
resectable CRLM have not been studied. Furthermore, the ability
of PET metabolic parameters (at baseline and in response to che-
motherapy) to predict conversion to resection of initially unre-
sectable CRLM has not been studied to date. The present study
specifically aims to define the ability of baseline and post-treat-
ment FDG PET-CT to predict conversion to resectability in the
setting of a Phase II clinical trial of HAIP chemotherapy for unre-
sectable CRLM. Secondary aims include an assessment of onco-
logic outcomes, as related to FDG PET-CT metabolic parameters.
Materials and methods
After approval had been gained from the Memorial Sloan–Ket-
tering Cancer Center Institutional Review Board, 49 patients
with unresectable CRLM were enrolled in a prospective Phase II
trial (clinicaltrials.gov ID: NCT00492999) evaluating the rate of
conversion to complete resection in patients with initially unre-
sectable liver-only metastases from colorectal cancer treated with
HAIP with floxuridine (FUDR) and dexamethasone (Dex) in
addition to best systemic chemotherapy combined with bev-
acizumab. Unresectability was prospectively determined by two
hepatobiliary surgeons and one radiologist and defined as tech-
nical (involvement of three hepatic veins, both portal veins or
the retrohepatic vena cava, or resection leaving less than two
adequately perfused and drained segments) or biological (more
than six metastases in a single lobe, with one lesion of ≥5 cm, or
six or more bilobar metastases). Responses that allowed resec-
tion with enough functional liver parenchyma (for technically
unresectable disease) or radiologically stable disease or response
(in biologically unresectable patients) prompted consideration
for resection with curative intent. Initial results, including the
oncologic outcomes of this trial, have been published previ-
ously.9 The present report centres exclusively on the role of FDG
PET-CT as a predictive and prognostic tool in this setting.
Chemotherapy regimen
Enrolled patients received systemic chemotherapy with either
oxaliplatin and irinotecan (for patients who had received up to
two cycles of oxaliplatin and had no persistent neuropathy) or
irinotecan plus 5-fluorouracil/leucovorin (5FU/LV) (for those
with prior treatment that included over two cycles of oxalipla-
tin). Both regimens included bevacizumab (5 mg/kg). Therapy
was given over a 4-week cycle. HAIP therapy with FUDR was
administered on day 1 of each cycle and the pump emptied
and filled with heparin and normal saline on day 15. Systemic
chemotherapy was administered on days 1 and 15 of each
cycle. Treatment recycled on day 29.
As part of the staging protocol, baseline FDG PET-CT and
diagnostic CT with angiography of the chest, abdomen and
pelvis were obtained. Patients were classified according to the
clinical risk score (CRS) as previously reported.29 Resectability
was reassessed jointly by two hepatobiliary surgeons and one
liver radiologist on CT scans performed every two cycles.
Patients considered to be resectable at restaging underwent lap-
arotomy with the intent of complete resection. Examination
with FDG PET-CT was repeated after cycles 3 and 6 and/or
before patients underwent hepatic resection.
FDG PET-CT
All scans were performed using PET-CT cameras, including the
Discovery LS, Discovery ST and Discovery STE (GE Healthcare,
Waukesha, WI, USA) or Biograph LSO-16 (Siemens Medical
Solutions, Malvern, PA, USA), without preference. Patients
fasted for 6 h before undergoing an 18F-FDG PET-CT scan.
Approximately 370–555 Mbq (12–15 mCi) of 18F-FDG was
injected i.v. Patients received oral contrast during the uptake
period. Low-dose CT (120–140 kV, 60–80 mA) and PET emis-
sion images were obtained from the base of the skull to the mid-
dle of the thigh at 60–90 min after injection. Reconstructed
images were loaded onto a PET VCAR (volume computer-assist-
ed reading) workstation (GE Healthcare, Milwaukee, WI, USA).
Volumetric regions of interest were placed over five index hepa-
tic lesions with the most abnormal 18F-FDG uptake. Region-of-
interest borders were set by manual adjustment in three planes.
A threshold of 42% of the maximum signal intensity was
used for segmentation of lesions. Maximum and average stan-
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dard uptake value (SUVmax and SUVavg), as well as total
lesion glycolysis (TLG), a measure of the SUV in relation to
the volume of each lesion, were calculated using PET VCAR
on baseline and follow-up scans.
Response parameters
Computed tomography response was determined using the
World Health Organization (WHO) criteria.30 Thus, a complete
response (CR) was indicated by the disappearance of all target
lesions. A partial response (PR) was indicated by a reduction of
≥50% from study baseline of all measured defects on CT. Stable
disease (SD) was indicated by a reduction of ≤50% and an
increase of <25% in summed products of all measured defects
on CT, and progressive disease (PD) was indicated by an
increase of ≥25% in the sum of the longest diameter of target
lesions. Metabolic response was determined as the percentage
change in the metabolic parameter (%Δ-MP) between serial
FDG PET-CT scans, and was applied to SUVmax and TLG.
Complete metabolic response was defined as a best response
of ≥95% in SUVmax. For SUVmax, response was calculated
after subtracting the background metabolic activity of the liver
(mean  standard deviation: 2.2  0.25). These responses
were calculated after two nuclear radiologists blinded to the
clinical outcomes independently reviewed all the available FDG
PET-CT scans. Pathologic response was derived from standard-
ized pathology reports of the resected specimens, which
included the degree of response to chemotherapy; the cut-off
used to determine a clinically relevant response was ≥75%, as
determined previously.31
Statistical considerations
All clinical and intervention data were collected prospectively.
Descriptive statistics were used to describe demographics and
baseline characteristics. Categorical variables are presented as
absolute numbers and percentages. Continuous variables are
presented as the median and interquartile range (IQR). Logistic
regression was used to assess the relationship between conver-
sion to resectability and the metabolic variables obtained at
baseline and follow-up FDG PET-CT scans. Correlations
between metabolic (PET), volumetric (CT) and pathologic
responses were evaluated with Pearson’s r. Survival was pre-
dicted with the Kaplan–Meier method and reported in months
with 95% confidence intervals (CIs). The impact of the meta-
bolic parameters on oncologic outcome (overall and liver pro-
gression-free survival) was evaluated with Cox regression. All
statistical analyses were performed using STATA Version 12.0
(StataCorp LP, College Station, TX, USA).
Results
Between 2007 and 2011, 49 patients were enrolled in the study.
Because of prior treatment with oxaliplatin, 59% of patients
(29/49) received systemic irinotecan + 5FU/LV in addition to
HAIP therapy. The remaining 20 received oxaliplatin-based
systemic chemotherapy. Grade 3 or 4 toxicity occurred in 41%
(20/49) of patients. The first 24 patients to be treated with bev-
acizumab showed a 54% toxicity rate, which included signifi-
cant biliary toxicity. Based on these and additional adverse
event data collected at the study institution,32–34 bevacizumab
was removed from the protocol; all other therapies remained
unchanged. The overall response rate was 76%.9
Metabolic activity on FDG PET and response to
therapy
Thirty-nine patients with a baseline FDG PET-CT scan were
included in this analysis. General demographics and presenta-
tion are detailed in Table 1. Thirty-eight patients had at least
one follow-up FDG PET-CT scan and 25 had a second follow-
up after six cycles of HAIP therapy. Most patients experienced
significant metabolic response. The median SUVmax response
was 83% (IQR: 75–92%). Complete metabolic response was
seen in 11% (n = 4) of patients, a metabolic response of ≥80%
in 58% (n = 22), and a metabolic response of ≥70% in 79%
(n = 30) of patients. Only three of 38 patients had a metabolic
response of <50%. The median TLG response was 92% (IQR:
85–97%). Data for FDG PET metabolic response are summa-
rized in Tables 2 and 3. Different degrees of metabolic
response are illustrated in Fig. 1.
Conversion to resection and pathologic response
Twenty of 38 (53%) patients had sufficient volumetric
response to be deemed resectable and underwent complete
resection after a median of 5 months (range: 5–7 months) of
therapy. There was no difference in the median percentage
Δ-SUV and Δ-TLG between patients who achieved resection
and those who did not (Table 3). Furthermore, baseline meta-
Table 1 Demographics and baseline characteristics in patients
with colorectal liver metastases submitted to 18F-FDG positron
emission tomography and computed tomography (PET-CT)
Patients (n) 39
Age, years, median (IQR) 56 (46–63)
Male, n (%) 23 (59%)
Clinical risk score, n (%)
2 3 (8%)
3 16 (41%)
4 13 (33%)
5 7 (18%)
Prior chemotherapy, n (%) 23 (59%)
Baseline 18F-FDG PET-CT, n (%) 39 (100%)
Lesions on imaging, n, median (IQR) 14 (7–24)
Largest tumour diameter, cm, median (IQR) 4 (3–6)
18F-FDG, 18F-fluorodeoxyglucose; IQR, interquartile range.
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bolic activity (SUVmax and TLG) and the percentage response
after therapy, used as continuous variables in a logistic regres-
sion analysis, were unable to predict which patients were more
likely to achieve resection (Table 5).
Most patients who underwent resection (18/20) experienced
an anatomical PR by WHO criteria on follow-up CT scans.
The other two showed minimal responses (SD by WHO crite-
ria) that were sufficient to allow complete resection. The only
patient in the entire cohort to experience a radiologic CR did
not come to resection and remains disease-free and off all ther-
apy at 57 months of follow-up. Most patients (13/20) had a
clinically significant pathologic response defined as a response
of >75% (Table 4). In two patients, no viable tumour was
identified on final pathology.
No linear relationship was identified between the volumetric
response on CT, the percentage change in the metabolic vari-
ables and the percentage of pathologic response (Table 4).
Median metabolic response was not greater in the 13 patients
with a clinically significant pathologic response [86% (range:
66–91%) versus 81% (range: 79–88%); P = 0.6]. The two
patients who achieved CR on pathology had metabolic
responses of 93% and 60%, respectively. However, only one of
four patients with a complete metabolic response underwent
resection and showed a pathologic response of 40%.
Furthermore, volumetric CT response did not correlate with
Δ-TLG and Δ-SUV on Pearson’s correlation (r = 0.1 and
r = 0.2, respectively). Moreover, metabolic variables and their
percentage change in response to therapy did not predict hepa-
tic RFS after resection (Table 5). Findings on FDG PET-CT
did not result in a change in therapy or in the detection of
unexpected extrahepatic disease in any patient.
Oncologic outcome
At a median follow-up time of 38 months for survivors (range:
32–52 months), median OS in all patients had not been
reached (95% CI 32 months–unknown) and the predicted
3-year OS was 54% (range: 33–71%). Median PFS was
13 months (95% CI 6–21 months) and 3-year PFS was 10%
(range: 3–20%). On Cox regression, none of the FDG PET
metabolic parameters were found to be associated with any of
the oncologic outcomes (Table 6).
(a) (b)
(c) (d)
Figure 1 Different patterns of response to hepatic arterial infusion
chemotherapy, showing (a, b) complete resolution of metabolic
activity and (c, d) a partial metabolic response.
Table 2 Metabolic parameters at baseline and post-hepatic arterial
infusion pump therapy by 18F-FDG positron emission tomography
(PET)
Median (interquartile range)
Metabolic
variable
Baseline
(n = 38)
First
follow-up
(n = 38)
Second
follow-up
(n = 25)
SUVmax 10.0 (7.0–13.0) 3.6 (2.8–4.0) 3.2 (2.5–4.0)
SUVavg 6.0 (4.0–8.0) 2.5 (2.2–2.8) 2.5 (2.0–3.0)
TLGmax 91.0 (40.0–213.0) 14.0 (5.0–39.0) 5.5 (2.0–17.0)
Liver
background
activity
2.3 (2.0–2.4) 2.2 (2.0–2.3) 2.1 (1.9–2.4)
Maximum
volume
39 (18–58) 11 (7–18) 6 (2–9)
18F-FDG, 18F-fluorodeoxyglucose; Maximum volume, maximal meta-
bolically active lesion volume; SUV, standard uptake value; TLG, total
lesion glycolysis.
Table 3 Metabolic response post-hepatic arterial infusion pump
therapy by 18F-FDG positron emission tomography (PET)
%D, median (interquartile range)
Metabolic
response
All patients
(n = 38)
Resection
(n = 20)
No resection
(n = 18)
P-valuea
SUVmax 83 (75–92) 83 (72–89) 83 (75–92) 0.4
TLG 92 (85–97) 90 (80–96) 93 (88–97) 0.2
a
Comparing resected and non-resected patients.
%D, percentage change; 18F-FDG, 18-fluorodeoxyglucose; SUV,
standard uptake value; TLG, total lesion glycolysis.
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Discussion
Although many consider FDG PET-CT to be an established
tool for the initial staging of patients with CRLM, it does not
have a proven role in monitoring disease during or after
chemotherapy. Cytotoxic chemotherapy decreases tumoral
hexokinase activity, preventing FDG from accumulating in
tumours and decreasing the metabolic parameters (SUV and
TLG). In a study by Akhurst et al., FDG PET-CT showed sen-
sitivity of 72% in detecting CRLM, which decreased to 63% in
patients who received concurrent fluoracil-based chemother-
apy.28 These tumours showed a 40% reduction in the activity
of hexokinase measured in frozen specimens at the time of
resection. In a retrospective study, Tan et al. specifically evalu-
ated CRLM in which a complete metabolic response was
achieved after neoadjuvant chemotherapy.26 In that study, 85%
of ‘PET-negative’ lesions were found to harbour viable tumour
upon histologic examination. Interestingly, patients who
showed both metabolic and radiologic response by RECIST
(response evaluation criteria in solid tumours) also had a high
false-negative rate (86%). A similar false-negative rate (87%)
was reported by Glazer et al.35 In the latter study, which evalu-
ated the ability of post-treatment FDG PET-CT to identify
liver lesions, only 11% of patients had negative FDG PET-CT
after chemotherapy (>90% received oxaliplatin-based therapy).
However, most of these (13/15) were false negatives and the
negative predictive value was 13%. The authors concluded that
FDG PET-CT performed within 4 weeks of chemotherapy for
CRLM is not reliable for restaging.35
Recently, a multi-institution, prospective, randomized con-
trolled trial evaluating the effect of preoperative PET-CT on
the surgical management of patients with resectable CRLM
showed that preoperative PET-CT did not alter surgical plans
(proposed after review of CT) in a significant proportion of
patients. Furthermore, the impact of PET-CT on survival by
way of enhanced patient selection was evaluated. No survival
difference was found between patients randomized to PET-CT
and controls (CT only).17 Although the patient populations
differ (resectable and unresectable CRLM), the conclusions of
this study, like those of the present investigation, strongly
question the routine use of PET-CT in the staging and follow-
up of patients with CRLM.
Until now, FDG PET-CT has not been studied in patients
receiving combination HAI and systemic chemotherapy. In the
present prospective study of HAI with FUDR and systemic
therapy for the treatment of uCRLM, half of the patients expe-
rienced enough radiologic response to be considered resectable.
The pathologic response among patients undergoing resection
varied significantly and only 10% (two of 20) of patients expe-
rienced a pathologic CR. Pathologic response did not correlate
with the degree of metabolic response. In one patient, who
showed a complete metabolic response and underwent resec-
tion, pathologic response was only 40%. However, the two
patients who achieved a CR had been found to have metabolic
responses of only 90% and 60%, which makes these data unin-
terpretable. Moreover, the percentage change in the metabolic
variables (metabolic response) as a continuous variable did
not predict conversion to resection or correlate with oncologic
outcome.
Table 4 Radiologic, metabolic and pathologic response in
resected patients
Resected patients, n (%) 20 (53%)
WHO response criteria, n
Partial response 18
Stable disease 2
Metabolic response, n
<70% 5
70–79% 3
80–94% 11
≥95% 1
Pathologic response, n
<75% 7
75–99% 11
100% 2
r-value of metabolic parameters versus PRa
CT % response 0.41
PET SUVmax % response 0.25
PET SUVavg % response  0.10
TLG % response 0.13
a
r-value was estimated using Pearson’s correlation.
PET, positron emission tomography; PR, pathologic response; SUV,
standard uptake value; TLG, total lesion glycolysis; WHO, World Health
Organization.
Table 5 Metabolic response in relation to conversion to resection
and recurrence-free survival in resected patients (n = 20)
Metabolic variables and conversion to resection OR (P-value)
SUVmax baseline 0.9 (0.2)
TLG baseline 0.9 (0.08)
PET SUVmax % response 0.24 (0.4)
TLG % response 0.04 (0.3)
Metabolic variables and Hep-RFS after resection HR (P-value)
PET SUVmax % response 1.00 (0.93)
PET SUVavg % response 1.01 (0.64)
TLG % response 1.00 (0.87)
SUVmax baseline 1.02 (0.67)
SUVavg baseline 1.01 (0.74)
TLG baseline 0.99 (0.63)
Hep-RFS, hepatic recurrence-free survival; HR, hazard ratio; OR, odds
ratio; PET, positron emission tomography; SUV, standard uptake value;
TLG, total lesion glycolysis.
HPB 2015, 17, 644–650 ª 2015 International Hepato-Pancreato-Biliary Association
648 HPB
The results of this study are in line with those reported by
Tan et al.26 and Glazer et al.35 regarding the lack of correlation
between metabolic and pathologic response. The cited studies,
however, did not address the issue of longterm oncologic out-
come in relation to metabolic activity before and after treatment.
This study evaluates the utility of non-standard metabolic
parameters (TLG, SUVmax, SUVavg) and their responses, which
have proven useful in other settings18,36,37 in predicting out-
comes in this cohort of patients. However, no clinically signifi-
cant correlation was apparent. Despite being used as a
prognostic marker in other malignancies,19–21,23 FDG PET-CT
does not seem to be an adequate prognostic or predictive marker
in patients with CRLM, particularly in those receiving HAI ther-
apy. No correlation between FDG PET-CT metabolic activity (or
metabolic response) and OS, PFS or hepatic RFS was found in
patients who underwent resection with curative intent.
The patient population in this study is unique. To the pres-
ent authors’ knowledge, this is the first study to prospectively
evaluate the ability of FDG PET-CT to predict conversion to
resection of initially unresectable disease based on metabolic
response parameters in patients receiving HAI and systemic
chemotherapy. Potential limitations include the fact that there
was no dedicated review of the available pathology. However,
routine pathology reports at the study institution include the
degree of response to chemotherapy expressed as a percentage;
the cut-off for a clinically relevant response (≥75%) was deter-
mined from the present group’s prior experience as reported
by Poultsides et al.31 Furthermore, FDG PET-CT response
was not the primary objective of the trial, but, rather, its inves-
tigation was built in as a correlative study and baseline FDG
PET-CT data were not available for all patients accrued. How-
ever, the fact that FDG PET-CT assessments were part of the
protocol allowed for standardization of technique and interpre-
tation in patients for whom FDG PET-CT scans were available.
Conclusions
In this series of patients with unresectable CRLM, responses
on FDG PET-CT proved unable to predict conversion to
resectability after treatment with a combination of HAI and sys-
temic chemotherapy. Furthermore, no correlation was identified
between metabolic response and pathologic response in resected
specimens and no prognostic value of the metabolic response
assessed with FDG PET-CT was ascertained. Based on these find-
ings, the present authors believe FDG PET-CT should not be used
to monitor treatment or in restaging after treatment with HAI
chemotherapy, or as a prognostic tool in this group of patients.
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